Skip to main content
. 2022 Feb 24;9:797297. doi: 10.3389/fcvm.2022.797297

Table 2.

Univariate and multivariate Cox proportional hazards regression analyses of NT-proBNP for predicting cardiovascular events.

Univariate analysis Age- and sex-adjusted Multivariate analysis
HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value
MACE
   Log (NT-proBNP) 1.70 (1.53–1.89) <0.001 1.46 (1.31–1.64) <0.001 1.47 (1.31–1.66) <0.001
   Low 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
   Median 2.11 (1.45–3.05) 0.001 1.94 (1.34–2.81) 0.001 1.88 (1.29–2.73) 0.001
   High 4.29 (3.03–6.06) <0.001 3.01 (2.09–4.34) <0.001 2.99 (2.06–4.36) <0.001
Hard endpoint
   Log (NT-proBNP) 2.35 (2.06–2.69) <0.001 1.67 (1.45–1.94) <0.001 1.70 (1.45–1.99) <0.001
   Low 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
   Median 3.07 (1.67–5.66) 0.001 2.61 (1.42–4.81) 0.001 2.52 (1.36–4.65) 0.003
   High 10.29 (6.41–16.87) <0.001 5.55 (3.08–9.98) <0.001 5.44 (2.99–9.90) <0.001
Cardiac mortality
   Log (NT-proBNP) 3.07 (2.59–3.64) <0.001 1.87 (1.55–2.26) <0.001 1.84 (1.51–2.25) <0.001
   Low 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
   Median 3.91 (1.50–9.21) 0.001 3.08 (1.18–8.05) 0.021 2.80 (1.07–7.33) 0.036
   High 12.08 (5.61–19.63) <0.001 6.99 (2.80–17.45) <0.001 5.92 (2.34–14.96) <0.001
All-cause mortality
   Log (NT-proBNP) 2.98 (2.57–3.44) <0.001 1.80 (1.53–2.11) <0.001 1.74 (1.47–2.06) <0.001
   Low 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
   Median 2.94 (1.41–6.12) 0.004 2.31 (1.11–4.82) 0.025 2.24 (1.07–4.67) 0.032
   High 14.91 (7.88–21.18) <0.001 5.36 (2.69–10.70) <0.001 5.03 (2.51–10.09) <0.001

MACE, major adverse cardiovascular events; NT-proBNP, N-terminal pro-brain natriuretic peptide; HR, hazard ratio; CI, confidence interval. Multivariate model is adjusted for age, sex, body mass index, family history of coronary artery disease, hypertension, smoking, diabetes, pre-revascularization, gensini score, left ventricular ejection fraction, low-density lipoprotein cholesterol, triglycerides, fasting plasma glucose, hypersensitive C-reactive protein and baseline statin use.